drugset / Trial / NCT03810105
A Study of Olaparib and Durvalumab in Prostate Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine if the combination of olaparib and durvalumab are better than the standard of care for treating prostate cancer.
Timeline
- Start
- 2019-03-07
- Primary completion
- 2023-07-06
- Completion
- 2023-07-06
Outcome
Outcome not reported
Stopped (Enrollment): “Due to low accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |
| Subject | Olaparib | Small molecule | 300 mg | — |